The DOI matches its Crossref record.
Insulin Resistance in Polycystic Ovary Syndrome: Progress and Paradoxes
Open accessAbstract
Over the past 20 years, it has been clearly documented that 1) polycystic ovary syndrome (PCOS) has major metabolic sequelae related to insulin resistance and 2) insulin resistance plays an important role in the pathogenesis of the reproductive abnormalities of the disorder. Women with PCOS are at significantly increased risk of developing type 2 diabetes mellitus (DM). Studies in isolated adipocytes and in cultured skin fibroblasts from PCOS women have demonstrated intrinsic postbinding defects in insulin-mediated glucose metabolism. In fibroblasts, the mitogenic pathway of insulin action is intact, consistent with a selective defect in insulin signaling. While PCOS skeletal muscle is resistant to insulin in vivo, cultured muscle cells have normal insulin sensitivity, consistent with a major role of extrinsic factors in producing insulin resistance in this tissue. Excessive serine phosphorylation of the insulin receptor or downstream signaling proteins may be involved in the pathogenesis of insulin resistance in PCOS. The putative serine kinase is extrinsic to the insulin receptor but its identity is unknown. The explanations for tissue-specific and signaling pathway-specific differences in insulin action in PCOS are unknown but may involve differential roles of insulin receptor substrate (IRS)-1 and IRS-2 in insulin signal transduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Self-citationFranks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Obesity and polycystic ovary syndrome
Barber, T. M., McCarthy, M. I., Wass, J. A. H., & Franks, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02587.x · Cited by 631
Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls
Legro, R. S., Castracane, V. D., & Kauffman, R. P. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000109523.25076.e2 · Cited by 453
Elsenbruch, S., Hahn, S., Kowalsky, D., Öffner, A. H., Schedlowski, M., Mann, K., & Janssen, O. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030562 · Cited by 437
Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies
Barber, T. M., Hanson, P., Weickert, M. O., & Franks, S. (2019) · Clinical Medicine Insights: Reproductive Health · doi:10.1177/1179558119874042 · Cited by 411
“In this sense, OSA is similar to PCOS (20-22).”
BackgroundObesity and polycystic ovary syndrome
Barber, T. M., & Franks, S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14421 · Cited by 385
High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome
Janssen, O., Mehlmauer, N., Hahn, S., Offner, A., & Gartner, R. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500363 · Cited by 322
Cardiometabolic Aspects of the Polycystic Ovary Syndrome
Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K., Nestler, J. E., Sattar, N., & Lehnert, H. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1003 · Cited by 322
Molecular mechanisms of insulin resistance in polycystic ovary syndrome
Diamanti-Kandarakis, E., & Papavassiliou, A. G. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.05.006 · Cited by 301
Magoffin, D. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.01.016 · Cited by 258
Barber, T. M., Wass, J. A. H., McCarthy, M. I., & Franks, S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02764.x · Cited by 254
Dumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222
Jensterle, M., Janez, A., Mlinar, B., Marc, J., Prezelj, J., & Pfeifer, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0857 · Cited by 47
“The cellular mechanisms underlying IR in PCOS are secondary to an early postreceptor defect in insulin-signalling cascade with a decreased downstream signal transduction in the face of normal insulin binding ( 12 ).”
BackgroundPuttabyatappa, M., Andriessen, V., Mesquitta, M., Zeng, L., Pennathur, S., & Padmanabhan, V. (2017) · Endocrinology · doi:10.1210/en.2017-00460 · Cited by 42
“In contrast, the increased plasma levels of HMW adiponectin, a biological active form that sensitizes tissues to insulin action (30), is inconsistent with the insulinresistant state of the prenatal T–treated animals, considering that hypoadiponectinemia is a feature of various animal models and patients with IR (30) a…”
BackgroundInfluentialCardiometabolic risk in patients with polycystic ovary syndrome.
Ozegowska, K., & Pawelczyk, L. (2015) · Polish Gynaecology · doi:10.17772/gp/59131 · Cited by 15
Metadata
- Authors
- Venkatesan, A. M.
- Venue
- Recent Progress in Hormone Research
- Publisher
- The Endocrine Society
- Published
- 2001-01-01
- Volume
- 56
- Issue
- 1
- Pages
- 295-308
- ISSN
- 0079-9963 (ISSN-L)
- OpenAlex
- W2119131931
- Cited by
- 164
- References
- 0
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.